Recently, children suffering from refractory neuroblastoma were treated with L1CAM-targeting CAR T cells in a clinical phase I trial (NCT02311621, https:clinicaltrials.gov) (4, 6). This evidence concerns the gene L1CAM and neuroblastoma.